Human Kidney Tubule-Specific Gene Expression Based Dissection of Chronic Kidney Disease Traits
暂无分享,去创建一个
Chengxiang Qiu | Y. Ko | K. Suszták | Jihwan Park | Ae Seo Deok Park | S. Han | P. Beckerman | M. Palmer | N. Ledó | Peter Choi
[1] Matthias Kretzler,et al. Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] Y. Ko,et al. MICROVASCULAR COMPLICATIONS — NEPHROPATHY ( M AFKARIAN , SECTION EDITOR ) Precision Medicine Approaches to Diabetic Kidney Disease : Tissue as an Issue , 2017 .
[3] G. Tse,et al. Animal models for the study of primary and secondary hypertension in humans , 2016, Biomedical reports.
[4] Yi Luan,et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study , 2016, The Lancet.
[5] Shinya Yamamoto,et al. Severity and Frequency of Proximal Tubule Injury Determines Renal Prognosis. , 2016, Journal of the American Society of Nephrology : JASN.
[6] M. Stegall,et al. Predicting Individual Renal Allograft Outcomes Using Risk Models with 1-Year Surveillance Biopsy and Alloantibody Data. , 2016, Journal of the American Society of Nephrology : JASN.
[7] K. Reidy,et al. Deletion of Lkb1 in Renal Tubular Epithelial Cells Leads to CKD by Altering Metabolism. , 2016, Journal of the American Society of Nephrology : JASN.
[8] B. Conway,et al. An Update on the Use of Animal Models in Diabetic Nephropathy Research , 2016, Current Diabetes Reports.
[9] A. Więcek,et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] S. Tatsunami,et al. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD , 2016, Clinical and Experimental Nephrology.
[11] K. Shedden,et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker , 2015, Science Translational Medicine.
[12] P. Mount,et al. Balancing the energy equation for healthy kidneys , 2015, The Journal of pathology.
[13] K. Ohashi,et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy , 2015, Diabetes/metabolism research and reviews.
[14] D. de Zeeuw,et al. Renal end points in clinical trials of kidney disease , 2015, Current opinion in nephrology and hypertension.
[15] Y. Ko,et al. Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD. , 2015, Journal of the American Society of Nephrology : JASN.
[16] C. Zeng,et al. Renal histologic changes and the outcome in patients with diabetic nephropathy. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] Kumar Sharma,et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development , 2014, Nature Medicine.
[18] J. Coresh,et al. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] A. Cheung,et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] Benjamin J. Keller,et al. Integrative biology identifies shared transcriptional networks in CKD. , 2014, Journal of the American Society of Nephrology : JASN.
[21] Xiao-ming Meng,et al. Inflammatory processes in renal fibrosis , 2014, Nature Reviews Nephrology.
[22] O. Troyanskaya,et al. Defining cell-type specificity at the transcriptional level in human disease , 2013, Genome research.
[23] G. Becker,et al. Animal models of chronic kidney disease: useful but not perfect. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[24] P. Clemons,et al. Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.
[25] A. Eddy,et al. Investigating mechanisms of chronic kidney disease in mouse models , 2012, Pediatric Nephrology.
[26] Glenda C Gobe,et al. Biomarkers in chronic kidney disease: a review. , 2011, Kidney international.
[27] K. Suszták,et al. Transcriptome Analysis of Human Diabetic Kidney Disease , 2011, Diabetes.
[28] K. Sharma,et al. Antifibrotic treatment and other new strategies for improving renal outcomes. , 2011, Contributions to nephrology.
[29] J. Navarro-González,et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy , 2011, Nature Reviews Nephrology.
[30] J. Wetzels,et al. The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[31] Li Yang,et al. Urinary Neutrophil Gelatinase-Associated Lipocalin: A Potential Biomarker for Predicting Rapid Progression of Drug-Induced Chronic Tubulointerstitial Nephritis , 2010, The American journal of the medical sciences.
[32] Jai Radhakrishnan,et al. Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[33] R. Star,et al. Major contribution of tubular secretion to creatinine clearance in mice. , 2010, Kidney international.
[34] C. Alpers,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[35] T. Ravasi,et al. Pirfenidone is renoprotective in diabetic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.
[36] D. Bolignano,et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[37] Audrey Kauffmann,et al. Bioinformatics Applications Note Arrayqualitymetrics—a Bioconductor Package for Quality Assessment of Microarray Data , 2022 .
[38] Steve Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[39] C. Marcantoni,et al. A perspective on arterionephrosclerosis: from pathology to potential pathogenesis. , 2007, Journal of nephrology.
[40] Tom Greene,et al. Surrogate end points for clinical trials of kidney disease progression. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[41] Richard J. Johnson,et al. Tubulointerstitial damage and progression of renal failure. , 2005, Kidney international. Supplement.
[42] S. Mackensen,et al. Relationship between glomerular lesions, serum creatinine and interstitial volume in membrano-proliferative glomerulonephritis , 1977, Klinische Wochenschrift.
[43] A. Fukamizu,et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. , 2004, The American journal of pathology.
[44] Benjamin M. Bolstad,et al. affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..
[45] Joseph P Grande,et al. Correlation of Quantitative Digital Image Analysis with the Glomerular Filtration Rate in Chronic Allograft Nephropathy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[46] Yung-Ming Chen,et al. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. , 2002, Journal of the American Society of Nephrology : JASN.
[47] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[48] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[49] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[50] R. Meyer,et al. Creatinine assay by the fuller's earth procedure or by enzymatic determination is adequate for urine but not plasma of mice. , 1993, Comparative biochemistry and physiology. B, Comparative biochemistry.
[51] G. Müller,et al. The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. , 1990, Pathology, research and practice.